Literature DB >> 19766384

Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort.

Hans-Martin Fritsche1, Maximilian Burger, Robert S Svatek, Claudio Jeldres, Pierre I Karakiewicz, Giacomo Novara, Eila Skinner, Stefan Denzinger, Yves Fradet, Hendrik Isbarn, Patrick J Bastian, Bjoern G Volkmer, Francesco Montorsi, Wassim Kassouf, Derya Tilki, Wolfgang Otto, Umberto Capitanio, Jonathan I Izawa, Vincenzo Ficarra, Seth Lerner, Arthur I Sagalowsky, Mark Schoenberg, Ashish Kamat, Colin P Dinney, Yair Lotan, Shahrokh F Shariat.   

Abstract

BACKGROUND: Management of T1 grade 3 (T1G3) urothelial carcinoma of the bladder (UCB), with its variable behaviour, represents one of the most difficult challenges for urologists and patients alike.
OBJECTIVE: To evaluate the characteristics and long-term outcome of patients with clinical T1G3 UCB treated with radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: Data from 1136 patients treated with RC for clinical T1G3 UCB without neoadjuvant chemotherapy were collected at 12 centres located in Europe, the United States, and Canada. Median age was 67 yr (range: 29-94), with a male-to-female ratio of 4:1. MEASUREMENTS: Patients' characteristics and outcome are evaluated. RESULTS AND LIMITATIONS: Of the 1136 patients, 33.4% had non-organ-confined stage at cystectomy, and 16.2% had lymph node (LN) metastasis; 49.7% were upstaged after RC to muscle-invasive disease, while 21.4% were downstaged to lower than T1G3. Within a median follow-up of 48 mo, 35.5% of patients died of metastatic UCB.
CONCLUSIONS: Approximately half of the patients treated with RC without neoadjuvant chemotherapy for clinical T1G3 UCB are upstaged to muscle-invasive UCB. These rates support the inadequacy of clinical decision making based on current treatment paradigms and staging tools. Therefore, identification of patients with clinical T1G3 disease at high risk of disease progression is of the utmost importance, as these patients are likely to benefit from early RC. Copyright 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19766384     DOI: 10.1016/j.eururo.2009.09.024

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  45 in total

Review 1.  [Urothelial carcinoma].

Authors:  H Rübben; F Vom Dorp
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

Review 2.  The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder.

Authors:  Romain Mathieu; Ilaria Lucca; Morgan Rouprêt; Alberto Briganti; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2016-07-19       Impact factor: 14.432

3.  HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC).

Authors:  Francesco Soria; Marco Moschini; Andrea Haitel; Gregory J Wirth; Jose A Karam; Christopher G Wood; Morgan Rouprêt; Vitaly Margulis; Pierre I Karakiewicz; Alberto Briganti; Jay D Raman; Solene-Florence Kammerer-Jacquet; Romain Mathieu; Karim Bensalah; Yair Lotan; Mehmet Özsoy; Mesut Remzi; Kilian M Gust; Shahrokh F Shariat
Journal:  World J Urol       Date:  2016-06-07       Impact factor: 4.226

4.  Les nouvelles du Réseau canadien du cancer de la vessie.

Authors:  D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

5.  Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience.

Authors:  Venu Chalasani; Wassim Kassouf; Joseph L Chin; Yves Fradet; Armen G Aprikian; Adrian S Fairey; Eric Estey; Louis Lacombe; Ricardo Rendon; David Bell; Ilias Cagiannos; Darrell Drachenberg; Jean-Baptiste Lattouf; Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

6.  Highlights from the canadian bladder cancer network.

Authors:  D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2011-04       Impact factor: 1.862

Review 7.  [Current developments in the diagnostics and therapy of bladder carcinoma].

Authors:  J Kamradt; C-H Ohlmann; M Stöckle
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

8.  [Transitional cell carcinoma of the bladder: bladder-sparing therapy].

Authors:  F Vom Dorp; S Tschirdewahn; T Szarvas; H Rübben; R Kraemer; C Rehme
Journal:  Urologe A       Date:  2014-09       Impact factor: 0.639

9.  Accuracy and prognostic value of variant histology and lymphovascular invasion at transurethral resection of bladder.

Authors:  Mohammad Abufaraj; Shahrokh F Shariat; Beat Foerster; Carmen Pozo; Marco Moschini; David D'Andrea; Romain Mathieu; Martin Susani; Anna K Czech; Pierre I Karakiewicz; Veronika Seebacher
Journal:  World J Urol       Date:  2017-11-11       Impact factor: 4.226

10.  Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer.

Authors:  Faysal A Yafi; Armen G Aprikian; Joseph L Chin; Yves Fradet; Jonathan Izawa; Eric Estey; Adrian Fairey; Ricardo Rendon; Ilias Cagiannos; Louis Lacombe; Jean-Baptiste Lattouf; Fred Saad; David Bell; Darrel Drachenberg; Wassim Kassouf
Journal:  World J Urol       Date:  2013-11-10       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.